VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Friday morning. The brokerage issued a sell rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research report on Thursday, March 20th.

VolitionRx Stock Performance

Shares of VNRX opened at $0.55 on Friday. The stock has a market capitalization of $50.97 million, a PE ratio of -1.53 and a beta of 1.09. The company’s fifty day moving average is $0.59 and its 200 day moving average is $0.64. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.02.

Insider Activity

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the company’s stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at approximately $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. Two Sigma Securities LLC purchased a new position in VolitionRx in the 4th quarter worth about $29,000. Millennium Management LLC bought a new stake in VolitionRx during the 4th quarter valued at about $36,000. Geode Capital Management LLC lifted its holdings in VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after buying an additional 1,481,000 shares during the period. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.